AKT1 and cancer: The activation of the main EPO/EPOR downstream pathways (JAK2-STAT5, PI3K-AKT, MAPK/ERK) has been demonstrated in cancer cells (Paes and Ringel, 2008; Thomas et al., 2015; Guo et al., 2020).